Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Earnings Routine +

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results

MediPharm Delivers Margin Recovery and Near-Breakeven EBITDA as International Sales Offset Domestic Stagnation

By The Northwire Desk — AI Analysis Mar 25, 2026 · 19:05 LABS · 0.07 MEDIPHARM LABS CORP. J
Executive Summary
  • MediPharm Labs reported full-year 2025 revenue of $45.1M, representing an 8% year-over-year increase, driven primarily by a 43% surge in international medical cannabis sales to $25.2M.
  • Q4 2025 revenue came in at $11.1M, slightly below Q4 2024's $12.0M, but international medical cannabis contributed $6.1M (55% of quarterly revenue).
  • Gross profit for FY2025 reached $14M (31% margin), with Q4 specifically showing a 35% margin ($3.9M), a notable recovery from the 22% margin compression highlighted in Q3 2025.
  • Adjusted EBITDA for the full year was a loss of $1.6M, an improvement of $0.3M versus 2024. Q4 adjusted EBITDA narrowed significantly to a loss of just $144K.
  • The company ended Q4 2025 with $10.8M in cash, remains virtually debt-free, and owns two production facilities appraised at over $15M.
  • Commercial shipments to France and Brazil were completed, with upcoming product launches planned for New Zealand, Australia, and Canada.
  • Operating expenses were reduced by 14% year-over-year on an adjusted basis, reflecting continued cost discipline under interim CEO Greg Hunter.
Material Impact
  • The results confirm management's Q3 2025 guidance that Q3 margins were a "low watermark" and that operational efficiencies would flow through in Q4. The 35% Q4 gross margin validates this claim.
  • Near-breakeven Q4 EBITDA (-$144K) demonstrates that the company is approaching operational cash flow neutrality, which reduces immediate dilution risk.
  • However, the 8% full-year revenue growth and slight Q4 top-line decline versus prior year indicate that international expansion is offsetting domestic stagnation rather than driving explosive growth.
  • The news is incremental and aligns with previously communicated strategic priorities. There are no surprise catalysts, unexpected partnerships, or material shifts in capital structure.
  • Given the penny-stock valuation and lack of profitability, the positive operational metrics are meaningful but do not fundamentally alter the risk profile or justify aggressive multiple expansion.
LABS · Price
Company Overview
  • MediPharm Labs is a Canadian pharmaceutical-grade cannabis producer and exporter focused on highly regulated international medical markets.
  • Flagship operations center on two owned, GMP-certified production facilities (including the Napanee site) that manufacture active pharmaceutical ingredients (API), oils, tinctures, dried flower, and proprietary metered-dose inhalers.
  • The company's core strategy relies on navigating complex regulatory frameworks to supply clinical research partners and medical distributors across the EU, UK, Australia, Brazil, and Canada.
  • Product differentiation is driven by advanced delivery technologies (metered-dose inhalers) and compliance with stringent pharmaceutical standards (FDA site registration, EU-GMP, ANVISA).
Read the original news release →

More from MEDIPHARM LABS CORP. J

May 28, 2026 · 08:00

MediPharm Labs Turns EBITDA Positive Amidst Revenue Contraction and Governance Shifts

Regulatory May 13, 2026 · 07:30

MediPharm Labs scrapes to adjusted EBITDA profitability in Q1 2026, but a veteran affairs reimbursement cut looms large over its direct-to-patient business.

Earnings Apr 27, 2026 · 08:30

US Rescheduling Confirmed, But Canadian Revenue Headwinds Loom

Regulatory Mar 30, 2026 · 07:45

MediPharm Posts Margin Recovery and Steady International Growth, Yet Profitability Remains Elusive

Earnings Jan 19, 2026 · 08:00

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

Management Jan 13, 2026 · 18:47

Medipharm Labs signs Costa Rica supply agreement

M&A / Property